Gestational diabetes overview

Revision as of 17:20, 7 December 2016 by Mehdi Pahlavani (talk | contribs)
Jump to navigation Jump to search

Diabetes mellitus main page

Gestational diabetes Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gestational Diabetes from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History and Prognosis

Complications

Maternal
Fetal and Neonatal

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Dietary Therapy

Medical Therapy

Primary Prevention

Secondary Prevention

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gestational diabetes overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gestational diabetes overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gestational diabetes overview

CDC on Gestational diabetes overview

Gestational diabetes overview in the news

Blogs on Gestational diabetes overview

Directions to Hospitals Treating Gestational diabetes

Risk calculators and risk factors for Gestational diabetes overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

Gestational diabetes (GDM) is a form of diabetes which affects pregnant women in second or third trimester who have never had diabetes before. There is no known specific cause, but it's believed that the hormones produced during pregnancy reduce a woman's receptivity to insulin resulting in high blood sugar.

Gestational diabetes mellitus (GDM) resembles type 2 diabetes in several respects, involving a combination of relatively inadequate insulin secretion and responsiveness. It occurs approximately 7.5 of all pregnancies in the United States and may improve or disappear after delivery. Even though it may be transient, untreated gestational diabetes can damage the health of the fetus or mother. Risks to the baby include macrosomia (high birth weight), congenital cardiac and central nervous system anomalies, and skeletal muscle malformations. Increased fetal insulin may inhibit fetal surfactant production and cause respiratory distress syndrome. Hyperbilirubinemia may result from red blood cell destruction.

Historical Perspective

  • Diabetes mellitus is an ancient term first found in Egyptian Eberes papyrus around 1500 BC. Hyperglycemia in pregnancy, first described by Bennewitz, a German physician in 1824. In 1950 GDM term was accepted.[1]
  • John B. O’Sullivan, Wilkerson and Remein in 1957 proposed offering a 3-hour oral glucose tolerance test (OGTT) for patients presenting risk factors for diabetes such as family history of diabetes, gestational glycosuria and overdeveloped infants at birth.[2]

Classification

Gestational diabetes refers to hyperglycemia during second or third trimester of pregnancy.[3] Diagnosis of diabetes in the second or third trimester of pregnancy that is not clearly either type 1 or type 2 diabetes.[3]

Pathophysiology

Insulin insensitivity

Insulin sensitivity reduces slightly during first and second trimesters but it decreases 40-60% during third trimester.[4][5][6] Other changes in molecular level that may lead to insulin resistant include: reduced ability of insulin to phosphorylate the insulin receptor, decreased expression of insulin receptor substrate 1 (IRS-1) and increased levels of a specific kinase.[7]

Factors affecting insulin insensitivity include: estrogens and progesterone[8], human chorionic somatomammotropin (hCS) or placental lactogen (HPL), prolactin, placental growth hormone variant (hGH-V), corticotropin-releasing factor (CRF) and corticotropin, leptin[9], tumor necrosis factor α (TNF-α)[10], adiponectin[11], resistin, ghrelin and interleukin-6.

Maternal metabolic changes

Basal and postprandial levels of glucose, FFAs, triglycerides, and amino acids are higher in GDM than of normal pregnancy.[12]

Maternal hyperglycemia leads to fetal hyperinsulinism, which is responsible for macrosomia and neonatal morbidity. Development of macrosomia (defined as birth weight >4000 g or above the 90th percentile for gestational age) is a frequent complication of pregnancies complicated by DM and GDM.
Increased adiposity is the primary component of the macrosomia. Infants of diabetic mothers may have up to twice the body-fat content of infants of normal mothers. [13]

Differentiating Gestational diabetes other Diseases

GDM must be differentiated from other causes of hyperglycemia during pregnancy for example diabetes type 1 or type 2.

Epidemiology and Demographics

Prevalence of gestational diabetes mellitus varies widely. It may range from 1% to 14% of all pregnancies.

The prevalence of GDM showed a 12% increase per year over the period from 1994 to 2002 in one study.[14] It's increasing rate over time, possibly is due to increases in mean maternal age and weight.[15]

In another study, Over the 7-year period, the age and race/ethnicity adjusted prevalence of GDM was from 7.5 per 100 in 1999 to 7.4 per 100 in 2005.[16] In one study ethnical prevalence of GDM was higher in Asian/Pacific Islanders (relative risk=1.97), Hispanic (RR=1.69) and African-American(RR=1.26) than for caucasian women after adjustment for year and maternal age.[16]

Risk Factors

Risk factors for gestational diabetes include:[17][18][19][20][21]

Screening

Screening can be performed during the first prenatal visit especially, if mother has risk factors for GDM. If the result is negative or test was not done during prenatal care, 24-28 weeks is the best time for screening mothers.[22][23]

50 gram Glucose Test

  • Regardless of fasting status of mother, 50 gram glucose is loaded and 1 hour later, plasma glucose level should be measured. Measures greater than 130 mg/dL are considered positive. Considering 130 mg/dl threshold has 88% to 99% sensitivity and 66% to 77% specificity.[24]
  • Next step is to confirm the diagnosis by performing a 100 gram 3 hour Glucose Test.

Natural History and Prognosis

  • Most of women with GDM return to their pre pregnancy glycemic status after delivery.
  • Women diagnosed with gestational diabetes have an increased risk of developing overt diabetes mellitus in the future. Women requiring insulin to manage gestational diabetes have a 50% risk of developing diabetes within the next five years. [25]
  • 1/3-2/3 women will re-experience GDM in subsequent pregnancies.[26][27]
  • Risk factors for recurrence include older age, multiparity, higher maternal weight in the index pregnancy and weight gain between pregnancies.[28][27]

Complications

  • Maternal complications of GDM can be categorized to obstetrical and long term glycemic status related complications.

Pre-eclampsia, polyhydramnios and difficult labor due to over weight baby are obstetrical complications. Risk of developing prediabetes or even overt diabetes is noticeable in GDM patients.[29][30][31]

Diagnosis

Diagnostic criteria

There are two method for diagnosis GDM.

One-step 75-g Oral glucose tolerance test and Two-step approach with a 50-g (nonfasting) screen followed by a 100-g OGTT for those who screen positive.

Both of them have good diagnostic yields and can improve diagnosis as early as possible.[34]

History and Symptoms

  • Usually there are no symptoms, or the symptoms are mild and not life threatening to the pregnant woman.[35]
  • Symptoms may include:

Physical Examination

There is no specific physical examination finding for gestational diabetes. Signs of insulin resistance (i.e. acanthosis nigricans) may be seen in physical examination.

Laboratory Findings

Generally a test for gestational diabetes is carried out between the 24th and 28th week of pregnancy.

If patient is at risk for gestational diabetes (see risk factors) he or she could prescribe a glucose test earlier in the pregnancy.

Treatment

After diagnosis, treatment starts with medical nutrition therapy, physical activity, and weight management depending on pregestational weight.[36]
Target glucose control in gestational diabetes are:

  • Fasting <95 mg/dL (5.3 mmol/L)
  • One-hour postprandial <140 mg/dL (7.8 mmol/L)
  • Two-hour postprandial <120 mg/dL (6.7 mmol/L)

Dietary Therapy

  • Many randomized controlled trials suggest that the risk of GDM may be reduced by diet, exercise, and lifestyle counseling.[37][38]
  • All women diagnosed with GDM require nutritional counseling for the appropriate amount of weight gain during pregnancy as well as dietary control. Women with a normal BMI [20-25], can consume about 30kcal/kg/d while those who are obese [BMI >25-34] should restrict their diet to 25 kcal/kg/d and those that have a BMI >34 should consume 20kcal/kg/d or less.
  • These patients should restrict fat intake and substitute simple or refined sugars in their diet to more complex carbohydrates.

Medical Therapy

Insulin Therapy

All insulins are pregnancy category B except for glargine, glulisine and degludec which are labeled category C. Insulin therapy in patients with GDM is based on pre-pregnancy BMI.

  • In the first trimester, the insulin requirement is approximately 0.7 units per kilogram times the pregnant weight of the woman.
  • By the second trimester, the insulin requirement is 0.8 units per kilogram.
  • By term, the insulin requirement is 0.9 times 1.0 unit per kilogram pregnant weight per day.[39]

Oral Hypoglycemics

Sulfonylureas

Recent studies showed that sulfonylureas, such as glyburide, may be inferior to insulin and metformin due to increased risk of neonatal hypoglycemia and macrosomia with this class.[40]

Metformin

It is associated with a lower risk of hypoglycemia and potential lower weight gain, may be preferable to insulin for maternal health if it suffices to control hyperglycemia however, metformin may slightly increase the risk of prematurity.[40][41][42]

Primary Prevention

Weight control, dietary control and life style modification are the main stay of preventing GDM.

Secondary Prevention

After delivery, mothers who diagnosed with GDM, should have close follow up to prevent overt diabetes in future. Testing with 75 g OGTT 6 to 12 weeks after delivery and then every 1-3 years is recommended for early diagnosis.

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

References

  1. Negrato CA, Gomes MB (2013). "Historical facts of screening and diagnosing diabetes in pregnancy". Diabetol Metab Syndr. 5 (1): 22. doi:10.1186/1758-5996-5-22. PMC 3644500. PMID 23634949.
  2. WILKERSON HL, REMEIN QR (1957). "Studies of abnormal carbohydrate metabolism in pregnancy; the significance of impaired glucose tolerance". Diabetes. 6 (4): 324–9. PMID 13447761.
  3. 3.0 3.1 "Standards of Medical Care in Diabetes-2016: Summary of Revisions". Diabetes Care. 39 Suppl 1: S4–5. 2016. doi:10.2337/dc16-S003. PMID 26696680.
  4. Catalano PM, Tyzbir ED, Wolfe RR, Calles J, Roman NM, Amini SB, Sims EA (1993). "Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes". Am. J. Physiol. 264 (1 Pt 1): E60–7. PMID 8430789.
  5. Buchanan TA, Metzger BE, Freinkel N, Bergman RN (1990). "Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes". Am. J. Obstet. Gynecol. 162 (4): 1008–14. PMID 2183610.
  6. Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA (1991). "Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women". Am. J. Obstet. Gynecol. 165 (6 Pt 1): 1667–72. PMID 1750458.
  7. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE (2007). "Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes". Diabetes Care. 30 Suppl 2: S112–9. doi:10.2337/dc07-s202. PMID 17596458.
  8. Freinkel N (1980). "Banting Lecture 1980. Of pregnancy and progeny". Diabetes. 29 (12): 1023–35. PMID 7002669.
  9. Lepercq J, Cauzac M, Lahlou N, Timsit J, Girard J, Auwerx J, Hauguel-de Mouzon S (1998). "Overexpression of placental leptin in diabetic pregnancy: a critical role for insulin". Diabetes. 47 (5): 847–50. PMID 9588462.
  10. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier JC, Huston-Presley L, Friedman JE, Kalhan SC, Catalano PM (2002). "TNF-alpha is a predictor of insulin resistance in human pregnancy". Diabetes. 51 (7): 2207–13. PMID 12086951.
  11. Retnakaran R, Hanley AJ, Raif N, Hirning CR, Connelly PW, Sermer M, Kahn SE, Zinman B (2005). "Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications". Diabetologia. 48 (5): 993–1001. doi:10.1007/s00125-005-1710-x. PMID 15778860.
  12. Metzger BE, Phelps RL, Freinkel N, Navickas IA (1980). "Effects of gestational diabetes on diurnal profiles of plasma glucose, lipids, and individual amino acids". Diabetes Care. 3 (3): 402–9. PMID 7190092.
  13. Catalano PM, Thomas A, Huston-Presley L, Amini SB (2003). "Increased fetal adiposity: a very sensitive marker of abnormal in utero development". Am. J. Obstet. Gynecol. 189 (6): 1698–704. PMID 14710101.
  14. Dabelea D, Snell-Bergeon JK, Hartsfield CL, Bischoff KJ, Hamman RF, McDuffie RS (2005). "Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program". Diabetes Care. 28 (3): 579–84. PMID 15735191.
  15. Feig DS, Hwee J, Shah BR, Booth GL, Bierman AS, Lipscombe LL (2014). "Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996-2010". Diabetes Care. 37 (6): 1590–6. doi:10.2337/dc13-2717. PMID 24705609.
  16. 16.0 16.1 Lawrence JM, Contreras R, Chen W, Sacks DA (2008). "Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005". Diabetes Care. 31 (5): 899–904. doi:10.2337/dc07-2345. PMID 18223030.
  17. Solomon CG, Willett WC, Carey VJ, Rich-Edwards J, Hunter DJ, Colditz GA, Stampfer MJ, Speizer FE, Spiegelman D, Manson JE (1997). "A prospective study of pregravid determinants of gestational diabetes mellitus". JAMA. 278 (13): 1078–83. PMID 9315766.
  18. Kim C, Liu T, Valdez R, Beckles GL (2009). "Does frank diabetes in first-degree relatives of a pregnant woman affect the likelihood of her developing gestational diabetes mellitus or nongestational diabetes?". Am. J. Obstet. Gynecol. 201 (6): 576.e1–6. doi:10.1016/j.ajog.2009.06.069. PMC 2789883. PMID 19691951.
  19. Gibson KS, Waters TP, Catalano PM (2012). "Maternal weight gain in women who develop gestational diabetes mellitus". Obstet Gynecol. 119 (3): 560–5. doi:10.1097/AOG.0b013e31824758e0. PMID 22353954.
  20. Retnakaran R, Shah BR (2016). "Impact of Twin Gestation and Fetal Sex on Maternal Risk of Diabetes During and After Pregnancy". Diabetes Care. 39 (8): e110–1. doi:10.2337/dc16-0825. PMID 27222507.
  21. Lucinda J. England , Richard J. Levine, Cong Qian, Lisa M. Soule, Enrique F. Schisterman, Kai F. Yu and Patrick M. Catalano (2004). "Glucose Tolerance and Risk of Gestational Diabetes Mellitus in Nulliparous Women Who Smoke during Pregnancy,". American Journal of Epidemiology. External link in |title= (help)
  22. "2. Classification and Diagnosis of Diabetes". Diabetes Care. 39 Suppl 1: S13–22. 2016. doi:10.2337/dc16-S005. PMID 26696675.
  23. Moyer VA (2014). "Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement". Ann. Intern. Med. 160 (6): 414–20. doi:10.7326/M13-2905. PMID 24424622.
  24. Donovan L, Hartling L, Muise M, Guthrie A, Vandermeer B, Dryden DM (2013). "Screening tests for gestational diabetes: a systematic review for the U.S. Preventive Services Task Force". Ann. Intern. Med. 159 (2): 115–22. doi:10.7326/0003-4819-159-2-201307160-00657. PMID 23712349.
  25. "Gestational Diabetes". Diabetes Mellitus & Pregnancy - Gestational Diabetes. Armenian Medical Network. 2006. Retrieved 2007-02-28. Text " Carla Janzen, MD, Jeffrey S. Greenspoon, MD " ignored (help)
  26. Getahun D, Fassett MJ, Jacobsen SJ (2010). "Gestational diabetes: risk of recurrence in subsequent pregnancies". Am. J. Obstet. Gynecol. 203 (5): 467.e1–6. doi:10.1016/j.ajog.2010.05.032. PMID 20630491.
  27. 27.0 27.1 MacNeill S, Dodds L, Hamilton DC, Armson BA, VandenHof M (2001). "Rates and risk factors for recurrence of gestational diabetes". Diabetes Care. 24 (4): 659–62. PMID 11315827.
  28. Moses RG (1996). "The recurrence rate of gestational diabetes in subsequent pregnancies". Diabetes Care. 19 (12): 1348–50. PMID 8941462.
  29. Yogev Y, Xenakis EM, Langer O (2004). "The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control". Am. J. Obstet. Gynecol. 191 (5): 1655–60. doi:10.1016/j.ajog.2004.03.074. PMID 15547538.
  30. Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev, Yogev (2010). "Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia". Am. J. Obstet. Gynecol. 202 (3): 255.e1–7. doi:10.1016/j.ajog.2010.01.024. PMC 2836485. PMID 20207245.
  31. Casey BM, Lucas MJ, Mcintire DD, Leveno KJ (1997). "Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population". Obstet Gynecol. 90 (6): 869–73. PMID 9397092.
  32. Mitanchez D, Burguet A, Simeoni U (2014). "Infants born to mothers with gestational diabetes mellitus: mild neonatal effects, a long-term threat to global health". J. Pediatr. 164 (3): 445–50. doi:10.1016/j.jpeds.2013.10.076. PMID 24331686.
  33. Widness JA, Teramo KA, Clemons GK, Voutilainen P, Stenman UH, McKinlay SM, Schwartz R (1990). "Direct relationship of antepartum glucose control and fetal erythropoietin in human type 1 (insulin-dependent) diabetic pregnancy". Diabetologia. 33 (6): 378–83. PMID 2199280.
  34. "Professional Practice Committee for the Standards of Medical Care in Diabetes-2016". Diabetes Care. 39 Suppl 1: S107–8. 2016. doi:10.2337/dc16-S018. PMID 26696673.
  35. Melmed, Shlomo (2015). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.
  36. Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, Hod M, Kitzmiller JL, Kjos SL, Oats JN, Pettitt DJ, Sacks DA, Zoupas C (2007). "Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus". Diabetes Care. 30 Suppl 2: S251–60. doi:10.2337/dc07-s225. PMID 17596481.
  37. Bain E, Crane M, Tieu J, Han S, Crowther CA, Middleton P (2015). "Diet and exercise interventions for preventing gestational diabetes mellitus". Cochrane Database Syst Rev (4): CD010443. doi:10.1002/14651858.CD010443.pub2. PMID 25864059.
  38. Koivusalo SB, Rönö K, Stach-Lempinen B, Eriksson JG (2016). "Response to Comment on Koivusalo et al. Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL): A Randomized Controlled Trial. Diabetes Care 2016;39:24-30". Diabetes Care. 39 (8): e126–7. doi:10.2337/dci16-0014. PMID 27457642.
  39. Jovanovic L, Druzin M, Peterson CM (1981). "Effect of euglycemia on the outcome of pregnancy in insulin-dependent diabetic women as compared with normal control subjects". Am. J. Med. 71 (6): 921–7. PMID 7032287.
  40. 40.0 40.1 Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R (2015). "Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis". BMJ. 350: h102. PMC 4301599. PMID 25609400.
  41. Jiang YF, Chen XY, Ding T, Wang XF, Zhu ZN, Su SW (2015). "Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials". J. Clin. Endocrinol. Metab. 100 (5): 2071–80. doi:10.1210/jc.2014-4403. PMID 25803270.
  42. Camelo Castillo W, Boggess K, Stürmer T, Brookhart MA, Benjamin DK, Jonsson Funk M (2015). "Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes". JAMA Pediatr. 169 (5): 452–8. doi:10.1001/jamapediatrics.2015.74. PMID 25822253.

Template:WH Template:WS